An in vivo and in vitro comparison of inhaled steroid delivery via a novel vortex actuator and a conventional valved holding chamber

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 5, 2007, Pages 471-479

  Menzies, Daniel ^a   Nair, Arun ^a   Pardon, Tom ^a   Barnes, Martyn ^a   Burns, Patricia ^a   Lipworth, Brian ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; METHACHOLINE;

ADRENAL FUNCTION; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROVOCATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 34248594980     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60762-4     Document Type: Article

References (28)

1. British guideline on the management of asthma. Thorax. 2003;58(suppl 1):i1-94.
2. Global Strategy for Asthma Management and Prevention: Global Initiative for Asthma (GINA). Washington, DC: National Institutes of Health National Heart Lung and Blood Institutes; 2005. Available at: www.ginasthma.org. Accessed June 1, 2006.
3. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213-219.
4. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl. 1982;119:101-104.
5. Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax. 1996;51:835-840.
6. Toogood JH, Jennings B, Baskerville J, Johansson SA. Clinical use of spacer systems for corticosteroid inhalation therapy: a preliminary analysis. Eur J Respir Dis Suppl. 1982;122:100-107.
7. Newman SP, Moren F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981;124:317-320.
8. O'Callaghan C, Barry P. Spacer devices in the treatment of asthma. BMJ. 1997;314:1061-1062.
9. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335-371.
10. Newman SP, Clarke SW. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest. 1993;103:1442-1446.
11. Fardon TC, Burns P, Barnes ML, Lipworth BJ. A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol. 2006;96:422-430.
12. Fowler SJ, Orr LC, Sims EJ, et al. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest. 2002;122:618-623.
13. Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med. 2004;1170:960-966.
14. Wildhaber JH, Waterer GW, Hall GL, Summers QA. Reducing electrostatic charge on spacer devices and bronchodilator response. Br J Clin Pharmacol. 2000;50:277-280.
15. Wildhaber JH, Devadason SG, Eber E, et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax. 1996;51:985-988.
16. Lipworth BJ, Lee DK, Anhoj J, Bisgaard H. Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. Br J Clin Pharmacol. 2002;54:544-547.
17. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107-1136.
18. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am J Respir Crit Care Med. 2005;171:912-930.
19. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161:309-329.
20. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14:32-38.
21. Inman MD, Hamilton AL, Kerstjens HA, Watson RM, O'Byrne PM. The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J Allergy Clin Immunol. 1998;101:342-348.
22. Chinn S, Schouten JP. Reproducibility of non-specific bronchial challenge in adults: implications for design, analysis and interpretation of clinical and epidemiological studies. Thorax. 2005;60:395-400.
23. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ; The AMPUL Study Group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med. 1999;159(4 pt 1):1043-51.
24. Ward C, Reid DW, Orsida BE, et al. Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clin Exp Allergy. 2005;35:1565-1571.
25. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715-1721.
26. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med. 2005;172:831-836.
27. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163-2173.
28. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483-494.